We confirmed that the transcriptional levels of HERV-K (HML-2) were significantly upregulated in lung cancer patients compared with healthy controls and provided insights into the relationship with the clinical characteristics of lung cancer patients. This evidence concerns the gene CLEC10A and lung carcinoma.